U.S.-listed shares of Zealand Pharma ZEAL, +1.83% ZEAL, +18.99% soared 21.2% in premarket trading on Thursday after the company said a Phase 3 clinical trial evaluating its investigational treatment f
Zealand Pharma A/S (ZEAL) Q1 2022 Earnings Conference Call May 12, 2022 10:00 AM ET Company Participants Matt Dallas - SVP and CFO Adam Steensberg - President and CEO Conference Call Participants Thom
Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q4 2021 Results - Earnings Call Transcript
Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.

Zealand Pharma A/S (NASDAQ:ZEAL) Stock Price Up 5.5%

05:46pm, Wednesday, 15'th Dec 2021 Dakota Financial News
Zealand Pharma A/S (NASDAQ:ZEAL)s stock price rose 5.5% during trading on Wednesday . The stock traded as high as $21.88 and last traded at $21.88. Approximately 228 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 16,498 shares. The stock had previously closed at $20.73. Separately, Zacks Investment []

Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Up to $21.30

08:16am, Sunday, 28'th Nov 2021 ETF Daily News
Zealand Pharma A/S (NASDAQ:ZEAL)s stock price gapped up prior to trading on Friday . The stock had previously closed at $21.30, but opened at $22.00. Zealand Pharma A/S shares last traded at $22.00, with a volume of 9 shares changing hands. Separately, Zacks Investment Research upgraded shares of Zealand Pharma A/S from a sell rating [] The post Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Up to $21.30 appeared first on ETF Daily News .

Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Down to $23.15

05:58pm, Wednesday, 24'th Nov 2021 Dakota Financial News
Shares of Zealand Pharma A/S (NASDAQ:ZEAL) gapped down before the market opened on Monday . The stock had previously closed at $23.15, but opened at $22.07. Zealand Pharma A/S shares last traded at $22.07, with a volume of 100 shares traded. Separately, Zacks Investment Research raised Zealand Pharma A/S from a sell rating to a []

Zealand Pharma A/S (NASDAQ:ZEAL) Hits New 52-Week Low at $22.33

10:24am, Sunday, 21'st Nov 2021 Transcript Daily
Zealand Pharma A/S (NASDAQ:ZEAL) reached a new 52-week low during trading on Friday . The stock traded as low as $22.33 and last traded at $23.15, with a volume of 1600 shares. The stock had previously closed at $23.09. Separately, Zacks Investment Research raised Zealand Pharma A/S from a sell rating to a hold rating []
Zealand Pharma A/S (NASDAQ:ZEAL) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, []
Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q3 2021 Results - Earnings Call Transcript
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE